Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy.

Autor:	Karlsson MJ; Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden., Costa Svedman F; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Tebani A; Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden., Kotol D; Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden., Höiom V; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Fagerberg L; Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden., Edfors F; Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden., Uhlén M; Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden.; Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.; Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark., Egyhazi Brage S; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. gianluca.maddalo@scilifelab.se Suzanne.Egyhazi.Brage@ki.se., Maddalo G; Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden. gianluca.maddalo@scilifelab.se Suzanne.Egyhazi.Brage@ki.se.
Jazyk:	angličtina
Zdroj:	Cancer research [Cancer Res] 2021 May 01; Vol. 81 (9), pp. 2545-2555. Date of Electronic Publication: 2021 Feb 11.
DOI:	10.1158/0008-5472.CAN-20-2000
Abstrakt:	Malignant cutaneous melanoma is one of the most common cancers in young adults. During the last decade, targeted and immunotherapies have significantly increased the overall survival of patients with malignant cutaneous melanoma. Nevertheless, disease progression is common, and a lack of predictive biomarkers of patient response to therapy hinders individualized treatment strategies. To address this issue, we performed a longitudinal study using an unbiased proteomics approach to identify and quantify proteins in plasma both before and during treatment from 109 patients treated with either targeted or immunotherapy. Linear modeling and machine learning approaches identified 43 potential prognostic and predictive biomarkers. A reverse correlation between apolipoproteins and proteins related to inflammation was observed. In the immunotherapy group, patients with low pretreatment expression of apolipoproteins and high expression of inflammation markers had shorter progression-free survival. Similarly, increased expression of LDHB during treatment elicited a significant impact on response to immunotherapy. Overall, we identified potential common and treatment-specific biomarkers in malignant cutaneous melanoma, paving the way for clinical use of these biomarkers following validation on a larger cohort. SIGNIFICANCE: This study identifies a potential biomarker panel that could improve the selection of therapy for patients with cutaneous melanoma. (©2021 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu